Wang M, Zhu X, Sha Z, Li N, Li D, Chen L
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Republic of China.
Br J Cancer. 2015 Mar 3;112(5):874-82. doi: 10.1038/bjc.2015.3. Epub 2015 Feb 10.
MiR-125b has critical role in non-small-cell lung cancer (NSCLC) cell migration, and its target genes have not been elucidated. Kinesin-1 light chain (KLC)-2 was predicted as one of miR-125b's targets by bioinformatics analysis. This study is to identify the function of KLC2 and its interaction with miR-125b in NSCLC.
Kinesin-1 light chain-2 protein expression and its clinical relevance were analysed in 140 matched NSCLC and adjacent non-neoplastic lung tissues. Both KLC2 gain- and loss-of-function analyses were performed in NSCLC cell lines by transient transfection. The direct interaction between KLC2 and miR-125b was confirmed by a luciferase reporter assay and a transient co-transfection assay as well as an analysis of eight matched clinical samples.
KLC2 protein was upregulated in NSCLC cell lines and tissues, and was an independent predictor of poor prognosis for elderly NSCLC patients. Kinesin-1 light chain-2 remarkably enhanced the invasive and migratory ability of NSCLC cells. MiR-125b inhibited KLC2 3'-untranslated region luciferase activity and protein expression, and inversely correlated with KLC2 expression in clinical samples. Kinesin-1 light chain-2 almost completely reversed miR-125b-induced inhibition on migration and invasion.
Kinesin-1 light chain-2 protein overexpression predicts poor survival in elderly NSCLC patients. Kinesin-1 light chain-2 acts as a proto-oncogene and a functional target of miR-125b in NSCLC cells.
微小RNA-125b(miR-125b)在非小细胞肺癌(NSCLC)细胞迁移中起关键作用,但其靶基因尚未阐明。通过生物信息学分析预测驱动蛋白-1轻链(KLC)-2是miR-125b的靶标之一。本研究旨在确定KLC2在NSCLC中的功能及其与miR-125b的相互作用。
分析140对匹配的NSCLC组织和相邻非肿瘤肺组织中驱动蛋白-1轻链-2蛋白表达及其临床相关性。通过瞬时转染在NSCLC细胞系中进行KLC2功能获得和功能缺失分析。通过荧光素酶报告基因检测、瞬时共转染检测以及对8对匹配临床样本的分析,证实KLC2与miR-125b之间的直接相互作用。
KLC2蛋白在NSCLC细胞系和组织中上调,是老年NSCLC患者预后不良的独立预测因子。驱动蛋白-1轻链-2显著增强NSCLC细胞的侵袭和迁移能力。miR-125b抑制KLC2 3'-非翻译区荧光素酶活性和蛋白表达,且在临床样本中与KLC2表达呈负相关。驱动蛋白-1轻链-2几乎完全逆转miR-125b诱导的对迁移和侵袭的抑制作用。
驱动蛋白-1轻链-2蛋白过表达预示老年NSCLC患者生存不良。驱动蛋白-1轻链-2在NSCLC细胞中作为原癌基因和miR-125b的功能靶标发挥作用。